BTC$62,618.00-0.25%
ETH$1,784.25+0.38%
USDT$0.9988-0.04%
BNB$569.17+0.14%
USDC$0.9999+0.01%
XRP$1.07-0.61%
SOL$75.19-1.62%
TRX$0.3249-1.59%
FIGR_HELOC$1.03+1.91%
HYPE$63.74-2.41%
DOGE$0.0723+0.10%
USDS$0.99970.00%
RAIN$0.0143-0.35%
LEO$9.54+0.05%
ZEC$507.59-1.85%
WBT$54.95-0.04%
BTC$62,618.00-0.25%
ETH$1,784.25+0.38%
USDT$0.9988-0.04%
BNB$569.17+0.14%
USDC$0.9999+0.01%
XRP$1.07-0.61%
SOL$75.19-1.62%
TRX$0.3249-1.59%
FIGR_HELOC$1.03+1.91%
HYPE$63.74-2.41%
DOGE$0.0723+0.10%
USDS$0.99970.00%
RAIN$0.0143-0.35%
LEO$9.54+0.05%
ZEC$507.59-1.85%
WBT$54.95-0.04%
BioNTech's $1.25 billion acquisition of CureVac creates a "German biotech champion" focused on mRNA-based cancer treatments, with CureVac shares surging 38% on the announcement.